SynAct Pharma AB (publ) (”SynAct” or the “Company”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announces that the Company has repurchased a total of 212,307 own shares as part of the share buyback program initiated by the Board of Directors.
The executed buybacks form part of the share buyback program of maximum SEK 5 million resolved by the Board of Directors of SynAct on 9 January 2026, based on the authorization from the extraordinary general meeting on 27 November 2025, which was announced on the same day. The share buyback program, which runs between 12 January 2026 and no later than 28 February 2026, is being carried out in accordance with the EU Market Abuse Regulation ("MAR") and the European Commission's Delegated Regulation 2016/1052 (the "Safe Harbour Regulation").
Shares in SynAct (ISIN: SE0008241491) have been repurchased as follows:
| Date | Aggregated daily volume (number of shares) | Weighted average share price per day (SEK) | Total daily transaction value (SEK) |
| 2026-01-12 | 32 187 | 22,972 | 739 406 |
| 2026-01-13 | 28 327 | 23,322 | 660 639 |
| 2026-01-14 | 30 039 | 23,725 | 712 675 |
| 2026-01-15 | 29 252 | 24,103 | 705 049 |
| 2026-01-16 | 30 420 | 23,879 | 726 387 |
| 2026-01-19 | 9 750 | 23,128 | 225 497 |
| 2026-01-20 | 21 022 | 22,838 | 480 092 |
| 2026-01-21 | 27 710 | 22,275 | 617 235 |
| 2026-01-22 | 500 | 21,900 | 10 950 |
| 2026-02-12 | 3 100 | 18,881 | 58 532 |
All acquisitions have been made on Nasdaq Stockholm by Mangold Fondkomission AB on behalf of SynAct. The total number of shares in SynAct, including own shares, amounts to 53,330,243. As of the date of this press release, SynAct’s holding of own shares amounts to 212,307.
For further information, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com
About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For more information: https://synactpharma.com/.